CureVac (CVAC) said Thursday the European Patent Office upheld a modified version of its mRNA patent after dismissing most of BioNTech's (BNTX) challenge in a case tied to their dispute over vaccine technology.
A hearing to determine whether BioNTech infringed the amended patent is scheduled for July 1 in a Dusseldorf court, CureVac said.
CureVac's shares were up more than 13% in recent Friday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.